Serum Institute subsidiary invests another $150M into Biocon
25 Apr 2023
Vaccine
Biosimilar manufacturer Biocon said Tuesday that the Serum Institute of India is making another $150 million investment, doubling a prior investment from last November.
This latest investment comes from Serum Life Sciences, a subsidiary of the Serum Institute based in the UK, which will see Biocon enter a a new arrangement to gain access to 100 million doses of Serum’s vaccines annually, along with the distribution rights to Serum’s vaccine portfolio. The vaccines will be a part of Biocon’s offerings for the wider global market.
Endpoints News
reached out to both Biocon and Serum for more information but did not receive a response by press time.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.